Genprex provides clinical trial updates for Acclaim-1, Acclaim-3, and diabetes gene therapy program

Genprex, Inc.

Acclaim-1 Phase 2a expansion enrolling; interim analysis after 19 patients expected H2 2025.
Acclaim-3 Phase 2 expansion opened; enrollment of first 25 patients for interim analysis expected H2 2025.
Diabetes gene therapy program licensed from Univ. of Pittsburgh; seeking FDA guidance for IND-enabling studies in H2 2025.
Acclaim-1 has FDA Fast Track; Acclaim-3 has Fast Track and Orphan Drug designations.
Initiated research on non-viral lipid nanoparticle delivery system for diabetes program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.